The Lungitude Foundation
The Lungitude Foundation improves survival rates and outcomes for lung transplant recipients and their carers. They are proud to be making a difference as a registered Australian charity by focusing on facilitating world-class clinical and research endeavours, medical procedures, therapies and support for pre and post lung transplant patients and their carers.
Clinical and research endeavours supported by the Lungitude Foundation benefit the lives of people who need or receive a lung transplant, on a national and global scale. All research funded by the Lungitude Foundation is translational, ‘bench to bedside’ health and medical research – which means research undertaken in the lab (‘the bench’) or in the clinics by the research teams, is translated into treatments or therapies that benefit people at the ‘bedside’ as soon as possible.
The Lungitude Foundation partners with leading medical and health organisations in the field of lung transplantation. They are a major benefactor of The Alfred Hospital Lung Transplant Research Team which is a world leader in optimising patient outcomes following lung transplantation.
The Alfred’s patient outcomes following lung transplantation remain the world’s best with 98% @ 1 year and 76% @ 5 year survival rates; figures that are significantly better than those reported by the International Society for Heart and Lung Transplantation Registry.
Gordon Jenkins, Lungitude Chair said ‘It means a lot to the Foundation to have Dye & Co as a corporate supporter. We are all about outcomes, the best outcomes for our patients. Like Dye and Co we are as much about preventative outcomes as we are about resolving problems in a positive manner. Our research positively impacts the transplant recipient, their family, carer and community.
Gordon further added “We no longer talk about an average 7 years life expectancy post-lung transplant. The research outcomes, many initially funded by the Foundation, means today we have recipients living 10, 15, 20 plus years post-transplant. Today we are focused on promoting clinical and research excellence delivering very realistic prospects of improving the health of all transplant patients, not just lung transplant recipients.”